Design Therapeutics, Inc.
DSGN · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | – | – | – | – |
| Cost of Goods Sold | $1 | $1 | $0 | $0 |
| Gross Profit | -$1 | -$1 | -$0 | $0 |
| % Margin | – | – | – | – |
| R&D Expenses | $44 | $57 | $49 | $25 |
| G&A Expenses | $18 | $21 | $19 | $11 |
| SG&A Expenses | $18 | $21 | $19 | $11 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | -$1 | -$1 | -$0 | $0 |
| Operating Expenses | $62 | $78 | $67 | $36 |
| Operating Income | -$62 | -$78 | -$68 | -$36 |
| % Margin | – | – | – | – |
| Other Income/Exp. Net | $13 | $11 | $4 | $0 |
| Pre-Tax Income | -$50 | -$67 | -$63 | -$36 |
| Tax Expense | $0 | $0 | $0 | $0 |
| Net Income | -$50 | -$67 | -$63 | -$36 |
| % Margin | – | – | – | – |
| EPS | -0.88 | -1.19 | -1.14 | -0.77 |
| % Growth | 26.1% | -4.4% | -48.1% | – |
| EPS Diluted | -0.88 | -1.19 | -1.14 | -0.77 |
| Weighted Avg Shares Out | 57 | 56 | 56 | 46 |
| Weighted Avg Shares Out Dil | 57 | 56 | 56 | 46 |
| Supplemental Information | – | – | – | – |
| Interest Income | $13 | $0 | $0 | $0 |
| Interest Expense | $0 | $0 | $0 | $0 |
| Depreciation & Amortization | $1 | $1 | $0 | $0 |
| EBITDA | -$49 | -$66 | -$63 | -$36 |
| % Margin | – | – | – | – |